Issue 9 - Mar 3, 2017
  • Conversation with The Cancer Letter

    Steve Hahn and his plan for rescuing MD Anderson

    Steve Hahn didn’t apply for the job of Chief Operating Officer at MD Anderson Cancer Center. In fact, there was no COO job to apply to, and conversations that preceded the announcement of his new role took less than a week.

  • Medicare payment in January helps MD Anderson reduce its operating losses

    MD Anderson Cancer Center reduced its year-to-date operating loss to $77.3 million in January, the fifth month of the fiscal year.

  • Cancer groups to Trump: FDA’s oncology division is NOT “slow and cumbersome”

    FDA’s approval process for drugs is “slow and cumbersome,” President Donald Trump said in his first address to a joint session of Congress on Feb. 28.

  • In Brief

    • Karmanos, Wayne State receive grant to conduct nation’s largest study of factors affecting African Americans with cancer
    • Feldman named chief of breast surgery & surgical oncology, director of breast cancer services at Montefiore and Einstein
    • Michael Rosen named chief communications officer at Pancreatic Cancer Action Network
    • Open Science Prize goes to software tool for tracking viral outbreaks
    • Fred Hutchinson announces Harold M. Weintraub Graduate Student Award winners
    • Boehringer Ingelheim, Vanderbilt expand collaboration to tackle hard-to-treat cancers
    • iKnowMed recognized as No. 1 oncology EHR by Black Book Research
    • CTCA, Allscripts, NantHealth to launch clinical pathways, custom oncology treatment platform
    • Blackfynn and CHOP expand partnership for data integration and analysis in pediatric brain tumors
  • Drugs and Targets

    • FDA approves Xermelo as first and only treatment for carcinoid syndrome diarrhea
    • FDA Accepts avelumab BLA for Priority Review for urothelial carcinoma
    • BMS expands International Immuno-Oncology Network with addition of Columbia and MacCallum Cancer Centre
    • Exelixis, BMS collaborate on late-stage combination trial in first-line RCC
    • Exelixis, Roche to evaluate cabozantinib and atezolizumab in solid tumors
    • Advaxis, SELLAS announce licensing agreement to develop antigen-targeting immunotherapy
Issue 8 - Feb 24, 2017
Issue 7 - Feb 17, 2017
  • Audit: Lynda Chin’s abandoned $62 million IBM Watson collaboration didn’t follow standard procedures

    An audit of an abandoned mega-project run by IBM Watson and MD Anderson Cancer Center found that the Houston-based institution skirted the UT System’s procurement regulations as it spent $62.1 million on an ill-fated artificial intelligence system.

  • Is it research or run-of-the-mill IT?

    The UT System report on the Oncology Expert Advisor Project raises questions about classification of development of artificial intelligence systems.

    Are they research or are they IT systems?

  • Guest Editorial

    The AACI Network Care Initiative

    Many cancer center hospital systems are expanding their services across large geographic regions, while cancer care is consolidating around ever enlarging groups.

    Over the next two years, as I serve as president of the Association of American Cancer Institutes, I will be leading an initiative to better define these networks and to develop methods of improving the quality of cancer care administered across individual cancer center networks, with better integration of treatment services, especially those now unique to our centers, into the community.

  • In Brief

    • Salk scientist awarded $500K Swedish prize
    • Prostate Cancer Foundation awards $8.6 million to eight teams
    • U.S. Preventive Services Task Force appoints three new members
    • BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology
    • Perthera, Hope for Stomach Cancer to provide patient services
    • RPRD Diagnostics, Children’s Minnesota to advance clinical pharmacogenomics
    • Jeffery Kutok named chief scientific officer at Infinity
    • CVS Health earns CEO Cancer Gold Standard accreditation
  • Drugs and Targets

    • Amgen submits Supplemental Biologics License Application for Blincyto
    • Pan-Canadian Pharmaceutical Alliance, BMS reach agreement on Opdivo
    • Immunomedics enters into licensing agreement with Seattle Genetics for Sacituzumab Govitecan
  • Funding Opportunities

    PCRP announces research awards application guidelines

    The Department of Defense Prostate Cancer Research Program is pre-announcing the application process for its funding awards even though due to the current Continuing Resolution, the Fiscal Year 2017 Defense Appropriations bill has not been passed to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.